Publication: Endocrine adverse events in patients treated with immune checkpoint inhibitors: a comprehensive analysis
Loading...
Program
Organization Authors
Co-Authors
Dokmetas, Meric
Muglu, Harun
Ozcan, Erkan
Helvaci, Kaan
Kalaci, Ender
Kahraman, Seda
Aykan, Musa Baris
Cicin, Irfan
Olmez, Omer Fatih
Bilici, Ahmet
Date
Language
Type
Embargo Status
No
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Background and Objectives: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but their use is associated with a spectrum of immune-related adverse events (irAEs), including endocrine disorders. This study aims to investigate the incidence, timing, treatment modalities, and impact of ICI-related endocrine side effects in cancer patients. Materials and Methods: This retrospective study analyzed 139 cancer patients treated with ICIs between 2016 and 2022. Data regarding endocrine irAEs, including hypothyroidism, hyperthyroidism, hypophysitis, and diabetes mellitus, were collected. The study examined the timing of irAE onset, management approaches, and the association between irAEs and treatment outcomes. Results: The most common endocrine irAE was hypothyroidism (65.5%), followed by hyperthyroidism (2.3%), hypophysitis (8.6%), and diabetes mellitus (0.7%). These disorders typically emerged within the first six months of ICI therapy. Most cases were managed conservatively or with hormone replacement therapy. Patients who developed endocrine irAEs exhibited a higher objective response rate (ORR) and clinical benefit rate (CBR) compared to those without irAEs. Conclusions: Endocrine dysfunction is a significant toxicity of ICI therapy. Early recognition, prompt diagnosis, and appropriate management are crucial to minimize their impact on patient health and quality of life. This study highlights the potential association between irAEs and improved clinical outcomes. Further research is needed to elucidate the underlying mechanisms and identify predictive biomarkers for irAE development.
Source
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Subject
Citation
item.page.haspartof
Source
Medicina
item.page.ispartofseries
item.page.edition
DOI
10.3390/medicina61010123
item.page.datauri
item.page.link
Rights
CC BY (Attribution)
Copyrights Note
Creative Commons license
Except where otherwise noted, this item's license is described as CC BY (Attribution)

